Wells Fargo & Company Eledon Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.54 - $2.13 $4 - $6	3 Added 1.61%	189 $0
Q4 2023 Feb 09, 2024	BUY	$1.12 - $1.86 $15 - $26	14 Added 8.14%	186 $0
Q3 2023 Nov 13, 2023	BUY	$1.14 - $1.66 $29 - $43	26 Added 17.81%	172 $0
Q2 2023 Aug 15, 2023	BUY	$1.34 - $2.85 $80 - $171	60 Added 69.77%	146 $0
Q1 2023 May 12, 2023	BUY	$2.0 - $3.46 $4 - $6	2 Added 2.38%	86 $0
Q4 2022 Feb 13, 2023	BUY	$2.17 - $2.75 $4 - $5	2 Added 2.44%	84 $0
Q3 2022 Nov 14, 2022	SELL	$2.45 - $3.88 $24 - $38	-10 Reduced 10.87%	82 $0
Q2 2022 Aug 12, 2022	BUY	$2.34 - $3.96 $9 - $15	4 Added 4.55%	92 $0
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.46 $23 - $33	-4 Reduced 4.35%	88 $1,000
Q2 2021 Aug 16, 2021	SELL	$7.62 - $11.75 $7 - $11	-1 Reduced 1.08%	92 $1,000
Q1 2021 May 13, 2021	BUY	$9.85 - $19.22 $916 - $1,787	93 New	93 $1,000

18.4M

Ticker ELDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,756,800
Market Cap $60M
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.